Category: MSA, PSP, CBS: Clinical Trials
Objective: This study aimed to explore the efficacy and safety of autologous adipose – derived stromal vascular fraction (SVF) in treating MSA.
Background: Multisystem atrophy is a rare and rapidly progressing neurodegenerative disease characterized by inclusion bodies composed of misfolded alpha synuclein in affected brain regions. Many scholars have proposed that the stromal vascular fraction (SVF) derived from fat can serve as an alternative source for cell therapy.
Method: Eight MSA patients were treated with SVF. SVF was prepared and administered via intravenous infusion and intrathecal injection. The efficacy after SVF treatment was evaluated by unified multiple system atrophy rating scale (UMSARS) Part Ⅰ and Part Ⅱ. Two experienced neurologists not involved in the treatment conducted the assessment. UMSARS scores were measured before treatment and at 1 and 3 months after treatment.
Results: (1) No treatment-related adverse events occurred, and there were no statistically significant differences in laboratory data before and after treatment. (2) The UMSARS I scores before treatment, at 1 and 3 months after treatment were 25.2 ± 3.25, 22.4 ± 3.12, 19.5 ± 2.37 respectively. The differences at 1 and 3 months after treatment compared with before treatment were statistically significant (P < 0.05). (3) The UMSARS II scores before treatment, at 1 and 3 months after treatment were 33.6 ± 3.03, 30.6 ± 3.63, 26.7 ± 3.41 respectively. The score at 1 month after treatment was slightly lower than before treatment without statistical difference (P > 0.05), while the score at 3 months after treatment was significantly lower with a statistically significant difference compared with before treatment (P < 0.05).
Conclusion: (1) SVF treatment for MSA is safe with no post-treatment adverse events. (2) The significant reduction in UMSARS I and II scores after SVF treatment indicates that SVF is effective in treating MSA.
Changes in UMSARS I score of patients
Changes in UMSARS II score of patients
Experimantal Flowchart
References: [1] Koh Y J, Koh B I, Kim H, et al. Arterioscler Thromb Vasc Biol, 2011, 31(5): 1141-1150.
[2] Morris M E, Beare J E, Reed R M, et al. Stem Cells Transl Med, 2015, 4(4): 369-380.
[3] Sahin U, Türeci Ö. Science, 2018, 359(6382): 1355-1360.
To cite this abstract in AMA style:
ZL. Cai, RX. Li, JW. Li. The effectiveness and safety of autologous adipose derived stromal vascular components (SVF) in the treatment of multiple system atrophy [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/the-effectiveness-and-safety-of-autologous-adipose-derived-stromal-vascular-components-svf-in-the-treatment-of-multiple-system-atrophy/. Accessed October 5, 2025.« Back to 2025 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-effectiveness-and-safety-of-autologous-adipose-derived-stromal-vascular-components-svf-in-the-treatment-of-multiple-system-atrophy/